These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 16522988)
21. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Gergely AE; Lafarge P; Fouchard-Hubert I; Lunel-Fabiani F Hepatology; 2002 May; 35(5):1281-2. PubMed ID: 11981781 [No Abstract] [Full Text] [Related]
22. Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin. Lin J; Lott JP; Amorosa VK; Kovarik CL J Am Acad Dermatol; 2009 May; 60(5):882-3. PubMed ID: 19389538 [No Abstract] [Full Text] [Related]
23. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease. Adinolfi LE; Durante Mangoni E; Andreana A Am J Gastroenterol; 2001 Feb; 96(2):607-8. PubMed ID: 11232725 [No Abstract] [Full Text] [Related]
24. [Dysacusia associated with pegylated-interferon and ribavirin combination therapy during chronic hepatitis C treatment: a report of two cases]. Jia YH; Gao SJ; Nan YM Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):67-8. PubMed ID: 22489302 [No Abstract] [Full Text] [Related]
25. Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Nishiofuku M; Tsujimoto T; Matsumura Y; Toyohara M; Yoshiji H; Yamao J; Fukui H; Yoshikawa M Intern Med; 2006; 45(7):483-4. PubMed ID: 16679707 [No Abstract] [Full Text] [Related]
26. [Acute pancreatitis during treatment for chronic viral hepatitis C]. Kabbaj N; Sentissi S; Guedira MM; Mohammadi M; Benaïssa A; Amrani N Gastroenterol Clin Biol; 2008 Mar; 32(3):232-3. PubMed ID: 18378105 [No Abstract] [Full Text] [Related]
27. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Fontana RJ; Schwartz SM; Gebremariam A; Lok AS; Moyer CA Psychosomatics; 2002; 43(5):378-85. PubMed ID: 12297606 [TBL] [Abstract][Full Text] [Related]
28. Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C. Musialik J; Petelenz M; Błoñska-Fajfrowska B; Hartleb M Eur J Gastroenterol Hepatol; 2009 May; 21(5):593-4. PubMed ID: 19194303 [No Abstract] [Full Text] [Related]
29. Cutaneous reactions to interferon and ribavirin. Chamberlain AJ; Poon E Intern Med J; 2004 Aug; 34(8):519. PubMed ID: 15317557 [No Abstract] [Full Text] [Related]
30. [Acute portal thrombosis in patients with hepatitis C treated with pegylated interferon and ribavirin]. Merino Rodríguez B; Díaz Sánchez A; Matilla Peña A; Clemente Ricote G; Núñez Martínez O Gastroenterol Hepatol; 2008 Jan; 31(1):18-21. PubMed ID: 18218275 [TBL] [Abstract][Full Text] [Related]
31. [Generalized eczema secondary to combined treatment with peginterferon alfa-2a and ribavirin in a patient with chronic hepatitis from the hepatitis C virus]. Ruiz de Casas A; García-Bravo B; Camacho F Actas Dermosifiliogr; 2005 Mar; 96(2):122-3. PubMed ID: 16476350 [TBL] [Abstract][Full Text] [Related]
32. [Central vein occlusion in a patient using interferon and ribavirin: case report]. Helal J; Zacharias LC; de Alencar LM Arq Bras Oftalmol; 2006; 69(4):601-4. PubMed ID: 17119740 [TBL] [Abstract][Full Text] [Related]
33. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin. Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173 [No Abstract] [Full Text] [Related]
34. Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. Bani-Sadr F; Goderel I; Lapidus N; Driss H; Simon A; Rosenthal E; Morand P; Lunel-Fabiani F; Pol S; Cacoub P; Perronne C; Carrat F; AIDS; 2008 Jul; 22(11):1385-7. PubMed ID: 18580626 [No Abstract] [Full Text] [Related]
35. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C. Rogers CJ; Romagosa R; Vincek V J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524 [No Abstract] [Full Text] [Related]
36. Side effects of medical therapy for chronic hepatitis C. Shiffman ML Ann Hepatol; 2004; 3(1):5-10. PubMed ID: 15118573 [TBL] [Abstract][Full Text] [Related]
37. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Demirturk N; Aykin N; Demirdal T; Cevik F Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483 [No Abstract] [Full Text] [Related]
38. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment. Vázquez-López F; Manjón-Haces JA; Pérez-Alvarez R; Pérez-Oliva N Br J Dermatol; 2004 May; 150(5):1046-7; author reply 1047. PubMed ID: 15149535 [No Abstract] [Full Text] [Related]
39. Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege. Ito T; Suzuki T; Funakoshi A; Tokura Y Eur J Dermatol; 2014; 24(5):631-3. PubMed ID: 25115439 [No Abstract] [Full Text] [Related]
40. An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment. Robaeys G; De Bie J; Van Ranst M; Buntinx F World J Gastroenterol; 2007 Apr; 13(16):2379-80. PubMed ID: 17511042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]